Multivessel PCI Does Not Improve 1-Year Survival in Patients With Multivessel Disease: Presented at AHA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Multivessel PCI Does Not Improve 1-Year Survival in Patients With Multivessel Disease: Presented at AHA

By Bruce Sylvester

ORLANDO, Fla -- November 18, 2009 -- Multivessel primary percutaneous coronary intervention (PCI) is not associated with a decrease in 1-year mortality in patients with multivessel disease (MVD) and ST-elevation myocardial infarction (STEMI) complicated with cardiogenic shock (CS), compared with culprit vessel-only PCI.

“Patients treated with multivessel PCI and patients treated with culprit vessel-only PCI had a comparable 1-year mortality, which was very high in both groups -- above 50%,” said lead investigator Bimmer Claessen, MD, Academic Medical Center at the University of Amsterdam, Amsterdam, the Netherlands, at a presentation on November 15 at the American Heart Association (AHA) Scientific Sessions 2009.

Between 1997 and 2005, Dr. Claessen and colleagues enrolled 161 consecutive patients with STEMI complicated with CS who had been admitted to 1 hospital site, and treated with primary PCI. They identified patients with MVD with a coronary angiogram and defined MVD at least 1 stenosis >50% in a non-infarct related coronary artery.

At the discretion of the clinicians, they performed multivessel PCI (23%; n = 37) or culprit vessel-only PCI (77%; n = 124).

Baseline patient characteristics were similar between groups. However, patients treated with multivessel primary PCI significantly more often received glycoprotein IIa/IIIb inhibitors during the procedure, compared with culprit vessel-only PCI (P = .03).

The investigators used standard statistical tools to evaluate and compare the data.

For the primary outcome, the researchers reported that 1-year mortality was comparable between patients in the multivessel and culprit vessel-only PCI groups (60% vs 52%, respectively; P = .45).

“This study is highly suggestive of the need for larger trials to study the relative efficacy of these 2 alternative procedures in this high-mortality patient population,” said Dr. Claessen.

[Presentation title: Multivessel Primary Percutaneous Coronary Intervention in Patients With Multivessel Disease and ST-Elevation Myocardial Infarction Complicated With Cardiogenic Shock. Abstract 4191]


E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities